Epicardial Fat Necrosis After COVID-19 Infection: A Case Report

Mohamad Zayour 1, Mahmoud Karaki 2, Rana Al Ashkar 3, Elie Chammas 4

1. Cardiology, University of Balamand, Beirut, LBN 2. Diabetes and Endocrinology, University of Balamand, Beirut, LBN 3. Internal Medicine, Faculty of Medicine, Lebanese University, Beirut, LBN 4. Cardiology, Clemenceau Medical Center, Beirut, LBN

Corresponding author: Mohamad Zayour, mhamad.zayour@hotmail.com

Abstract

Epipericardial or epicardial fat necrosis (EFN) is a self-limited inflammatory process occurring in the mediastinal fat surrounding the heart. It is an uncommon cause of acute chest pain and mimics more critical clinical disorders such as acute coronary syndrome, aortic dissection, and pulmonary embolism. However, EFN is frequently overlooked and under-recognized in emergency departments (EDs) owing to the unfamiliarity of this condition among physicians and radiologists. Herein, we present the case of a previously healthy young male patient, with a recent history of mild COVID-19 infection (two weeks before presentation), who presented to the ED for acute chest pain. Paraclinical evaluation including computed tomography (CT) of the chest revealed fat stranding along with the left epicardial fat pad in favor of EFN.

Categories: Cardiology, Internal Medicine, Infectious Disease
Keywords: epipericardial fat necrosis, covid-19, case report, sars-cov-2, epicardial fat necrosis

Introduction

One of the most common causes of emergency department (ED) admissions is chest pain. The latter has a vast differential diagnosis varying from mild to lethal conditions. EFN is an unusual benign cause of chest pain and is often not acknowledged [1].

To our knowledge, there are no reports linking COVID-19 infection to epicardial fat necrosis (EFN) in Lebanon. Thus, here we submit a case of EFN in a young male patient with a recent history of COVID-19 infection.

Case Presentation

A 19-year-old male patient, previously healthy, presented to the ED for acute onset chest pain and dyspnea. A review of the systems is significant for smoking history, vaccinated double dose against SARS-CoV-2, with a recent (two weeks prior to presentation) polymerase chain reaction (PCR)–proven COVID-19 infection consisting of generalized fatigue and fever without any associated respiratory symptoms (mild disease course). Family history is not significant for any cardiac disease. The chest pain started a few days before the current presentation, mainly left-sided, radiating to the left shoulder, and pleuritic in nature with no other symptoms.

Upon ED presentation, he was afebrile, normotensive, not tachycardic nor tachypneic. The patient denied local tenderness and no friction rub was heard during cardiac auscultation. In addition to the laboratory tests, shown in Table 1, troponin was not detectable. Electrocardiogram was performed and showed no abnormalities (Figure 1 and Table 2).
| Test                      | Value                | Normal Range       |
|--------------------------|----------------------|--------------------|
| WBCs                     | 8.97 x10^3 /microL   |                    |
| Hemoglobin               | 13.5 g/dL            |                    |
| Platelet count           | 248 000/microL       |                    |
| Creatinine               | 0.64                 |                    |
| D-Dimer                  | 188 ng/mL            | Normal: <255       |
| C-reactive protein (CRP) | 2.834                | Normal: <1         |
| Troponin Level           | <0.01 ng/mL          |                    |

**TABLE 1: The initial laboratory results**

Further investigations included a chest x-ray (CXR) that turned out normal (Figure 2). On the following day of admission, C-reactive protein (CRP) and D-dimer trended upward (6,739 mg/dL and 330 ng/mL, respectively). Accordingly, echocardiography was performed with a normal result, and a CT angiography of the chest was done showing no evidence of pulmonary embolism with normal lung parenchyma. However, fat stranding along with the left epipericardial fat pad (Figures 3, 4) was noted suggesting fat necrosis. Before confirming the diagnosis, pericarditis was ruled out by the absence of the following: pericardial effusion on...
CT, chest pain in the presentation, and that EKG changes.

**FIGURE 2:** Chest x-ray showing no abnormal findings

**FIGURE 3:** CT angiocoronal view showing pericardial fat stranding (blue arrow).
Hence, the diagnosis of EFN secondary to COVID-19 infection was made. The patient was discharged on colchicine and non-steroidal anti-inflammatory drugs with subsequent improvement of symptoms observed during his follow-up appointment after one week of discharge.

Discussion
EFN is an unusual benign disease initially portrayed in 1957 by Jackson et al. [2,3]. The common presentation is acute pleuritic chest pain that can mimic other serious diseases [4].

The actual rate of this disorder is unspecified because of its limited events. However, there has been a growth in the documentation of EFN in recent years, possibly due to the better imaging modalities, thus the incidence is estimated at 2.2% in patients who underwent chest CT for chest pain in the ED [5]. Although EFN is considered an inflammatory process that takes place within the epipericardial fat leading to encapsulated necrosis, similarly to fat necrosis in breast tissue after injury, peripancreatic fat in pancreatitis and epiploic appendagitis [1,6], the exact pathophysiology is not well established with some suggested mechanisms still under investigations.

SARS-CoV-2 being known as a respiratory causing illness did not have a fully explained mechanism of action (ACE2 moderated direct myocardial damage, hypoxia-induced destruction, microvascular injury, and SIRS) to elaborate its effect on other organs. It is known to have caused a wide range of clinical conditions from asymptomatic to respiratory failure. However, it also appeared to have had an important effect on the cardiac system. Those cardiac manifestations were varying from heart failure to arrhythmias, myo/pericarditis, and even sudden cardiac death [7]. Indeed, coronavirus (COVID-19) induced EFN has not been reported in the literature previously, but the mechanism underlying such inflammatory condition might be explained by the fact that epicardial adipose tissue (EAT), having the biggest proportions of lipogenesis and fatty acid metabolism among the visceral fat depots thus displaying thermogenic, mechanical, and metabolic properties, is a target for SARS-CoV-2 through ACE2 and the inflammatory cytokines interleukin-6 (IL-6), tumor necrosis factor- (TNF) α which are expressed at high levels across this tissue. Subsequently, such interaction promotes an augmented cascade of inflammatory processes leading to myocardial and surrounding structures complications including EFN [8].
Considering the clinical manifestation, EFN typically presents as chest discomfort in healthy individuals. It is a pleuritic pain, moderate to drastic in intensity, principally left-sided and some patients also experience shortness of breath on exertion. Our patient presented with the symptoms reported in the literature [9].

Physical examination is mostly unremarkable with normal laboratory results of creatine kinase and troponin [10]. Raised CRP levels were recorded in a few patients, probably due to the inflammatory process [11], which explains the lab value reported in the case we present. Electrocardiograms, as well as echocardiography, are non-specific in most cases [12]. EFN can be diagnosed by CT scan or CMR with characteristic imaging features [1].

Concerning its management, EFN had been treated primarily with thoracotomy and surgical excision in the past [13]. Nevertheless, due to the advancement in CT scan machines and their spatial resolution, a conservative approach toward management has been adopted, usually with non-steroidal anti-inflammatory medications for one to two weeks leading to symptom improvement [13]. And follow up by imaging after a few months to evaluate the resolution that has been proposed [1,14]. But, there resides a part for thoracotomy and surgery when the diagnosis remains skeptical and underlines a possibility of thoracic tumors.

Conclusions
The list of differential diagnoses for COVID-19 patients presenting with chest pain to the ER department is long and ranges from EFN to myocardial infarction. EFN is an uncommon cause of acute chest pain. Yet, due to its benign, and self-limited course, it must not be overlooked in contrast to other life-threatening conditions.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICJME uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Giassi Kde S, Costa AN, Bachion GH, Apanavicius A, Filho JR, Kairalla RA, Lynch DA: Epipericardial fat necrosis: an underdiagnosed condition. Br J Radiol. 2014, 87:20140118. 10.1259/bjr.20140118
2. Hernández D, Galimany J, Pernas JC, Llanger J: Case 170: pericardial fat necrosis. Radiology. 2011, 259:919-22. 10.1148/radiol.10090786
3. Jackson RC, Clagett OT, McDonald JR: Pericardial fat necrosis: report of three cases. J Thor Surg. 1957, 33:725-9. 10.1067/s0006-5588(20)30480-3
4. Pineda V, Cáceres J, Andreu J, Vilà J, Domingo ML: Epipericardial fat necrosis: radiologic diagnosis and follow-up. 2005, 185:1254-6. 10.2214/AJR.04.1310
5. Giassi KS, Costa AN, Bachion GH, Kairalla RA, Filho JR: Epipericardial fat necrosis: who should be a candidate?. AJR Am J Roentgenol. 2016, 207:773-7. 10.2214/AJR.15.15934
6. Vasei N, Shishhegar A, Ghalkhani F, Darvishi M: Fat necrosis in the breast: a systematic review of clinical . Lipids Health Dis. 2019, 18:139. 10.1186/s12944-019-1078-4
7. Fried JA, Ramsasubbu K, Bhatt R, et al.: The variety of cardiovascular presentations of COVID-19 . Circulation. 2020, 141:1950-6. 10.1161
8. In-Chool Kim, Seongwook Han,: Epidocardial adipose tissue: fuel for COVID-19-induced cardiac injury?. European Heart J. 2020, 41:2534-5. 10.1095
9. Shah AH, Bogale V, Hurst D, dePrisco G: Epipericardial fat necrosis as a cause of acute chest pain . Proc (Bayl Univ Med Cent). 2016, 29:432-3. 10.1148/radiol.10090786
10. van den Heuvel FM, Dimitriu-Leen AC, Habets J, Nijveldt R: Epipericardial fat necrosis: an underdiagnosed condition. Br J Radiol. 2014, 87:20140118. 10.1259/bjr.20140118
11. Zafar MR, Mustafa SF, Shabbir A, Warrainch S, Altaf A: Epipericardial fat necrosis: a concise review of literature. Cureus. 2021, 13:e15106. 10.7759/cureus.15106
12. Bhatt MY, Martinez-jiménez S, Rosado-de-christenson ML, Watson KR, Walker CM, Kunin JR: Imaging manifestations of mediastinal fat necrosis. Case Rep Radiol. 2015, 2015:325579. 10.1155/2015/325579
13. Baig A, Campbell B, Russell M, Singh J, Borra S: Epidipcardial fat necrosis: an uncommon etiology of chest pain . Cardiol J. 2012, 19:424-8. 10.5603/cj.2012.0076
14. Cafezheiro CR, Lopes MP, Silva CT, et al.: Epipericardial fat necrosis as cause of chest pain in patient after heart transplantation. Am J Transplant. 2020, 20:1451-3. 10.1111/ajt.15744